

96TH CONGRESS  
2D SESSION

# S. 2892

To amend the patent law to restore the term of the patent grant for the period of time that non-patent regulatory requirements prevent the marketing of a patented product.

---

## IN THE SENATE OF THE UNITED STATES

JUNE 27 (legislative day, JUNE 12), 1980

Mr. BAYH (for himself, Mr. THURMOND, Mr. MATHIAS, Mr. MORGAN, and Mr. PERCY) introduced the following bill; which was read twice and referred to the Committee on the Judiciary

---

## A BILL

To amend the patent law to restore the term of the patent grant for the period of time that non-patent regulatory requirements prevent the marketing of a patented product.

1 *Be it enacted by the Senate and House of Representa-*  
 2 *tives of the United States of America in Congress assembled,*  
 3 That this Act may be cited as the "Patent Term Restoration  
 4 Act of 1980."

5 SEC. 2. (a) The Congress finds that—

87m2  
7/15/80

1           (1) the United States patent system has provided  
2 a major incentive for the investment necessary for in-  
3 novation and new product development;

4           (2) protection of health and the environment is a  
5 necessary concern of the Federal Government and  
6 many patented products may not be marketed commer-  
7 cially until the product has been approved in accord-  
8 ance with various Federal health and environmental  
9 laws;

10          (3) the time necessary for the testing of such  
11 products and the regulatory review or notification  
12 period substantially reduce the period of commercial  
13 exclusivity which the Congress intended a patented  
14 product to enjoy;

15          (4) such a reduction in the commercial exclusivity  
16 period discourages research and innovation and pre-  
17 vents important new products from being made avail-  
18 able to the public;

19          (5) restoration of the rights afforded by the grant  
20 of patents to their full period of exclusivity is a neces-  
21 sary prerequisite to restoring the United States to an  
22 innovative leadership position.

23          (b) It is the policy of the United States that the term of  
24 patents for products subject to premarketing regulatory  
25 review or notification should be extended to compensate for

1 delays in commercialization of such products resulting from  
2 government regulation.

3       SEC. 3. Title 35 of the United States Code, entitled  
4 "Patents" is amended by adding the following new section  
5 immediately after section 154:

6 "**§ 155. Restoration of patent term**

7       “(a)(1) Except as provided in paragraph (2), the term of  
8 a patent which encompasses within its scope a chemical  
9 product, a process for use of a chemical product, or a device  
10 subject to a regulatory review period shall be extended by the  
11 amount of time equal to the regulatory review period for such  
12 chemical product or device if—

13               “(A) the owner of record of the patent gives  
14 notice to the Commissioner in compliance with the pro-  
15 visions of subsection (b)(1);

16               “(B) the regulatory review period resulted in the  
17 removal of restrictions on the commercial marketing of  
18 such product or device; and

19               “(C) the patent has not expired prior to notice to  
20 the Commissioner under subsection (b)(1).

21 The rights derived from any claim of any patent so extended  
22 shall be limited in scope during the period of any extension to  
23 the chemical product or device subject to the regulatory  
24 review period and to the statutory use for which regulatory  
25 review was required.

1           “(2) In no event shall the term of any patent be ex-  
2 tended for more than seven years.

3           “(b)(1) Within ninety days after termination of a regula-  
4 tory review period, the owner of record of the patent shall  
5 notify the Commissioner that the regulatory review period  
6 has ended. Such notification shall be in writing and shall:

7           “(A) state the date on which the regulatory  
8 review period commenced and ended;

9           “(B) identify the device or specify the chemical  
10 identity of the chemical product and the statutory use  
11 for which regulatory review was required;

12           “(C) state that the requirement of subsection  
13 (a)(1)(B) has been satisfied; and

14           “(D) identify the claim of the patent to which the  
15 extension is applicable and the length of time of the  
16 regulatory review period for which the term of such  
17 patent is to be extended.

18           “(2) Upon receipt of the notice required by paragraph  
19 (1), the Commissioner shall promptly publish the information  
20 noticed in the Official Gazette of the Patent and Trademark  
21 Office.

22           “(3) The Commissioner shall issue a certificate of exten-  
23 sion, under seal, stating the fact and length of the extension  
24 and identifying the product or device and the use and the  
25 claim to which such extension is applicable. Such certificate

1 shall be recorded in the official file of each patent extended,  
2 and such certificate shall be considered as part of the original  
3 patent.

4       “(4) Any patent extension granted under this section  
5 shall be revoked by the Commissioner if the person subject to  
6 the regulatory review period is convicted by a court of a  
7 criminal violation for submitting false, fictitious, fraudulent,  
8 or misleading data in support of the application, petition, re-  
9 quest, or notification described in subsection (c)(4) on which  
10 such patent extension is based.

11       “(c) As used in this section:

12           “(1) The term ‘chemical product’ means—

13               “(A) any new drug, new animal drug, food  
14               additive, or color additive as defined in section  
15               201 of the Federal Food, Drug, and Cosmetic  
16               Act;

17               “(B) any human or veterinary biological  
18               product as defined in section 351(a) of the Public  
19               Health Service Act or in regulations issued under  
20               the virus, serum, toxin and analogous products  
21               provisions of the Act of Congress of March 4,  
22               1913;

23               “(C) any pesticide as defined in section 2 of  
24               the Federal Insecticide, Fungicide, and Rodenti-  
25               cide Act; and

1           “(D) any chemical substance or mixture as  
2           defined in section 3 of the Toxic Substances Con-  
3           trol Act.

4           “(2) The term ‘device’ means any device as de-  
5           fined in section 201(h) of the Federal Food, Drug, and  
6           Cosmetic Act and described in section 513(a)(1)(C) of  
7           such Act.

8           “(3) The term ‘major health or environmental ef-  
9           fects test’ means an experiment to determine or evalu-  
10          ate health or environmental effects which requires at  
11          least six months to conduct, not including any period  
12          for analysis or conclusions.

13          “(4) The term ‘regulatory review period’ means—

14               “(A) with respect to a new drug or a human  
15               biological product, a period commencing on the  
16               date the patentee, his assignee, or his licensee has  
17               requested an exemption for investigation with re-  
18               spect to such drug or biological product under  
19               section 505(i) or section 507(d) of the Federal  
20               Food, Drug, and Cosmetic Act and ending on the  
21               date an application with respect to such drug sub-  
22               mitted under section 505(b) or section 507(f) of  
23               such Act is approved or such biological product is  
24               licensed under section 351(d) of the Public Health  
25               Service Act;

1           “(B) with respect to a new animal drug, a  
2           period commencing on the date the patentee, his  
3           assignee, or his licensee has requested an exemp-  
4           tion for investigation with respect to such animal  
5           drug under section 512(j) of the Federal Food,  
6           Drug, and Cosmetic Act and ending on the date  
7           an application with respect to such animal drug  
8           submitted under section 512(b) of such Act is  
9           approved;

10           “(C) with respect to a veterinary biological  
11           product, a period commencing on the date the  
12           patentee, his assignee, or his licensee has re-  
13           quested authority to prepare an experimental  
14           product under the virus, serum, toxin, and analo-  
15           gous products provisions of the Act of Congress of  
16           March 4, 1913, and ending on the date such bio-  
17           logical product is licensed under such Act;

18           “(D) with respect to a food additive, a period  
19           commencing on the date the patentee, his as-  
20           signee, or his licensee initiates a major health or  
21           environmental effects test relied upon to establish  
22           the safety of such food additive in a petition sub-  
23           mitted under section 409 of the Federal Food,  
24           Drug, and Cosmetic Act requesting issuance of a  
25           regulation prescribing the conditions under which

1 such additive may be safely used and ending on  
2 the date such regulation becomes effective;

3 “(E) with respect to a color additive, a  
4 period commencing on the date the patentee, his  
5 assignee, or his licensee initiates a major health  
6 or environmental effects test relied upon to show  
7 that such color additive will be safe for its in-  
8 tended uses in a petition requesting the issuance  
9 of a regulation listing such use and ending on the  
10 date such a regulation becomes effective;

11 “(F) with respect to a pesticide, a period  
12 commencing on the earlier of the date the pat-  
13 entee, his assignee, or his licensee (i) initiates a  
14 major health or environmental effects test on such  
15 pesticide, the data from which is submitted in a  
16 request for registration of such pesticide under  
17 Section 3 of the Federal Insecticide, Fungicide,  
18 and Rodenticide Act, (ii) requests the grant of an  
19 experimental use permit under section 5 of such  
20 Act, or (iii) submits an application for registration  
21 of such pesticide pursuant to section 3 of such  
22 Act, and ending on the date such pesticide is first  
23 registered, either conditionally or fully;

24 “(G) with respect to a chemical substance or  
25 mixture for which notification is required under



1 section 5(a) and which is subject to a rule requir-  
2 ing testing under section 4(a) of the Toxic Sub-  
3 stances Control Act, a period commencing on the  
4 date the patentee, his assignee, or his licensee has  
5 initiated the testing required in such rule and  
6 ending on the expiration of the premanufacture  
7 notification period for such chemical substance or  
8 mixture, or if an order or injunction is issued  
9 under section 5(e) or 5(f) of such Act, the date on  
10 which such order or injunction is dissolved or set  
11 aside;

12 “(H) with respect to a chemical substance or  
13 mixture for which notification is required under  
14 Section 5(a) but which is not subject to a testing  
15 rule under Section 4 of the Toxic Substances  
16 Control Act, a period commencing on the earlier  
17 of the date the patentee, his assignee, or his  
18 licensee—

19 (i) submits a premanufacture notice, or

20 (ii) initiates a major health or environ-

21 mental effects test on such substance, the

22 data from which is included in the premanu-

23 facture notice for such substance,

24 and ending on the expiration of the premanufac-

25 ture notification period for such substance or if an

1 order or injunction is issued under section 5(e) or  
2 5(f) of such Act, the date on which such order or  
3 such injunction is dissolved or set aside; and

4 “(I) with respect to a device, a period com-  
5 mencing on the date the patentee, his assignee or  
6 his licensee has requested an exemption for inves-  
7 tigation with respect to such device under section  
8 520(g) of the Federal Food, Drug, and Cosmetic  
9 Act and ending on the date an application with  
10 respect to such device submitted under section  
11 515(c) of such Act is approved,

12 except that the regulatory review period shall not be  
13 deemed to have commenced until a patent has been  
14 granted for the chemical product or device or the use  
15 of such product or device subject to the regulatory  
16 review period. In the event the regulatory review  
17 period has commenced prior to the effective date of  
18 this section, then the commencement of the regulatory  
19 review period shall be considered to be such effective  
20 date.”.